Dekkun develops a humanized monoclonal antibody, DKN-01, for the treatment of cancer and for strengthening cancer-associated bone lesions.
Industries BiotechnologyHealth CareHeadquarters Regions Greater Boston Area, East Coast, New England Founded Date 2011 Operating Status Active Last Funding Type Venture - Series Unknown
Company Type For Profit
Dekkun Corporation is in stealth mode, it intends to develop pharmaceutical technologies. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.